Utilization of Extreme Drug Resistance Testing in Malignant Melanoma: new is not Always Better.

  • Kelly Martens

Student thesis: Doctoral Thesis

Abstract

This study evaluates the treatment decisions made using a multi-disciplinary approach within the Yale Cancer Center Melanoma Unit regarding patients with malignant melanoma relative to information contained in EDR tests conducted by Oncotech Inc. Within this comparison, three specific outcomes consistent with hypotheses of the study were assessed: the utilization of test results, drug toxicity and cost effectiveness and survival.
Date of Award4 Feb 2006
LanguageEnglish
Awarding Institution

Cite this

Utilization of Extreme Drug Resistance Testing in Malignant Melanoma: new is not Always Better.
Martens, K. (Author). 4 Feb 2006

Student thesis: Doctoral Thesis